If your email program has trouble displaying this email, view as a webpage. FDA to Discuss COVID-19's Impact on Medical Product Operations at SBIA REdI Annual Conference In the face of the COVID-19 pandemic, the U.S. Food and Drug Administration has worked hard to help facilitate the timely development of medical products. We have used our emergency authorities to make these products available to the public as soon as possible, provided the criteria for issuance are met. We have also kept our partners in public health — industry, health care providers, consumers, congressional leaders, and other stakeholders — updated of our actions and the decisions we have made throughout the pandemic.     The FDA's three human medical product centers— the Center for Drug Evaluation and Research (CDER), the Center for Devices and Radiological Health (CDRH), and the Center for Biologics Evaluation and Research (CBER) — will co-host the Small Business Industry and Assistance (SBIA) Regulatory Education for Industry (REdI) Annual Conference to provide an overview of our regulatory operations during COVID-19. The annual event, which will run July 19-23, 2021, marks SBIA's 10th anniversary and will be the first time that CDER, CDRH, and CBER are all participating.

Stay Connected with U.S. Food and Drug Administration:

SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA